Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2652W HIGH $1.57
Volume
166.71 K
Value Traded
4.23 M
Short % Float
23.08%
+3.05%Week
+7.57%1 Month
-13.56%3 Month
-58.01%6 Month
-94%5 Year
-99.85%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
68.22 M
EPS (TTM)
-0.18
P/E Ratio
-
Ent. Value
59.27 M
Total Shares
189.88 M
Float Shares
187.95 M
Insiders
1.00%
Institutions
70.48%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HRTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Heron Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Heron Therapeutics, Inc.
435Total events
6Upcoming
135Tier-1 (high impact)
2011 to 2032Coverage
Upcoming catalysts 2
Event history 50
▲Timing GuidancePresentation
Planned sales force expansion for Acute Care franchise on track for Q3 2026
▼IP Litigation RulingCINVANTIApprovedIP / Competition
U.S. District Court holds CINVANTI patents invalid
chemotherapy-induced nausea and vomitingsource ↗
▲IP Litigation RulingCINVANTIApprovedIP / Competition
Settlement reached with Baxter Healthcare Corporation in CINVANTI patent litigation; case dismissed
chemotherapy-induced nausea and vomitingsource ↗
▲Timing GuidanceAPONVIEApprovedPresentation
APONVIE permanent J-code (J8502) became active April 1, 2026
postoperative nausea and vomitingsource ↗
▲Enrollment MilestoneCINVANTIApprovedTrial
CINVANTI surpassed 5 million demand units sold since launch
chemotherapy-induced nausea and vomitingsource ↗
●Quarterly UpdateCorporate
Full-year 2026 net revenue guidance of $173-$183 million and adjusted EBITDA of $10-$20 million issued
▲Timing GuidanceZYNRELEFDiscontinuedPresentation
IGNITE 2.0 program extended through 2026 with 40% increase in target accounts from January 2026
postoperative painsource ↗
▲Reimbursement / PricingZYNRELEFDiscontinuedPost-Market
CMS granted permanent product-specific J-Code (J0668) for ZYNRELEF effective October 1, 2025
postoperative painsource ↗
▲Product LaunchZYNRELEFDiscontinuedPost-Market
Vial Access Needle (VAN) transition complete for ZYNRELEF
postoperative painsource ↗
▲Product LaunchAPONVIEApprovedPost-Market
Dedicated APONVIE sales team launched in Q3 2025
postoperative nausea and vomitingsource ↗
▲Quarterly UpdateCorporate
Updated 2025 full-year guidance for net revenue and adjusted EBITDA
▲Debt Royalty FinancingCorporate
Completion of comprehensive capital restructuring to reduce debt and extend maturities
▲Hatch Waxman LitigationCINVANTIApprovedIP / Competition
Settlement with Mylan resolving CINVANTI patent litigation
chemotherapy-induced nausea and vomitingsource ↗
▲Hatch Waxman LitigationAPONVIEApprovedIP / Competition
Settlement with Mylan resolving APONVIE patent litigation
chemotherapy-induced nausea and vomitingsource ↗
▲Other Regulator MilestoneZYNRELEFDiscontinuedEx-US Regulatory
Effective date for ZYNRELEF under CMS Non-Opioid Policy for Pain Relief
postoperative painsource ↗
●Quarterly UpdateCorporate
Corporate headquarters relocation from San Diego to Cary, NC effective January 1, 2025
▲Reimbursement / PricingAPONVIEApprovedPost-Market
CMS granted permanent product-specific J-Code (J8502) for APONVIE
postoperative nausea and vomitingsource ↗
▲Oral PresentationAPONVIEApprovedPresentation
Inclusion of APONVIE in Fifth Consensus Guidelines for Management of PONV
postoperative nausea and vomitingsource ↗
▲Other Regulator MilestoneZYNRELEFDiscontinuedEx-US Regulatory
Separate reimbursement provision for non-opioid pain treatments begins
non-opioid treatment for pain relief in outpatient settingsource ↗
▲IP Litigation RulingCINVANTIApprovedIP / Competition
U.S. District Court upholds validity of CINVANTI patents in litigation against Fresenius Kabi
chemotherapy-induced nausea and vomitingsource ↗
▲Product LaunchZYNRELEFDiscontinuedPost-Market
Expected launch of ZYNRELEF VAN
postoperative painsource ↗
◆Timing GuidanceZYNRELEFDiscontinuedPresentation
FDA action date for ZYNRELEF VAN PAS expected within 4-6 months
postoperative painsource ↗
▲Manufacturing MilestoneZYNRELEFDiscontinuedCMC / Inspection
FDA approval of Prior Approval Supplement Application for ZYNRELEF Vial Access Needle (VAN)
postoperative painsource ↗
▲FDA ApprovalZYNRELEFDiscontinuedFDA Decision
FDA approval of ZYNRELEF Vial Access Needle (VAN)
postoperative painsource ↗
◆PDUFA DateZYNRELEFDiscontinuedRegulatory Filing
ZYNRELEF VAN PDUFA goal date set for September 23, 2024
postoperative painsource ↗
▲Other Regulator MilestoneZYNRELEFDiscontinuedEx-US Regulatory
CMS Proposed Rule includes ZYNRELEF as qualifying product under Non-Opioid Policy for Pain Relief
postoperative painsource ↗
▲FDA Filing AcceptedZYNRELEFDiscontinuedRegulatory Filing
FDA acknowledged receipt of Prior Approval Supplement application for ZYNRELEF VAN
postoperative painsource ↗
●sNDA SubmissionZYNRELEFDiscontinuedRegulatory Filing
Prior Approval Supplement submission to FDA for ZYNRELEF Vial Access Needle
postoperative painsource ↗
◆Oral PresentationPresentation
CEO fireside chat at 23rd Annual Needham Virtual Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How HRTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-09-25 | ZYNRELEF® Vial Access Needle | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D36 / 100
Pipeline Score
$70M
Pipeline Value
$151M
Commercial Value
Undervalued
Valuation Signal
4
Drugs Scored
3.6x
rNPV / MCap
Top 51%
Micro Cap(rank 336 of 658)
Percentile Rank
Heron Therapeutics, Inc. faces pipeline headwinds (36/100), with $281M risk-adjusted pipeline value, led by HTX-011A in Postoperative Pain (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $151.2M x 1.0 = $151M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| CINVANTI | $89M | $99M | -10.3% |
| ZYNRELEF | $43M | $31M | +39.4% |
| APONVIE | $15M | $8M | +86.2% |
| SUSTOL | $4M | $12M | -62.5% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HTX-011A Small moleculeCompletedNCT02762929 | Postoperative Pain | Phase 2 | COMPLETED | 430 | Mar 1, 2017 |
Clinical Trial Results
Readouts, endpoints and source filings for every HRTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ZYNRELEF | postpartum pain management in women undergoing Caesarean sections | Phase 2 | 2022-05-16 | pain scores: mild range; opioid free recovery: 27%; opioid rescue medication: 69% lessRead More | Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hensley Mark EarlOfficer (Chief Operating Officer) | Option | 31,250 179,789 held | $0.00 | 08/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HRTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0.1 % (-66.7 %) | 2.67 M | 6.25 M |
HRTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HRTX ranks across every disease it competes in
Competitive Position is a premium feature
See how HRTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHRTX News
HRTX▼ -31.7%on this news
Heron Therapeutics Announces Second Quarter 2026 Financial Results
Heron Therapeutics reported a net revenue of $37.7 million for Q2 2026, reflecting a 9% increase from the previous quarter. The company's products ZYNRELEF® and APONVIE® showed strong performance, with revenue growth of 35% and 74% year-over-year, respectively. Additionally, Heron amended its credit facility with Hercules Capital, resetting financial covenants through 2027.
Read more →HRTXHeron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026
Heron Therapeutics has announced a conference call to discuss its second quarter 2026 financial results, scheduled for August 10, 2026. The call will take place at 8:30 a.m. and will be accessible via live webcast. This event reflects the company's commitment to keeping stakeholders informed about its financial performance.
Read more →HRTX▼ -45.6%on this news
U.S. District Court Issues Decision Regarding CINVANTI Patents After Reviewing the Ruling, Heron Believes It has Substantial Grounds for Obtaining Reversal in an Appeal
Heron Therapeutics, Inc. announced that the U.S. District Court for the District of Delaware ruled against its patents for CINVANTI, declaring them invalid. Despite the setback, Heron intends to appeal the decision in hopes of reversal in the United States Court of Appeals for the Federal Circuit. The company emphasizes its commitment to defending its intellectual property rights. This ruling does not affect prior settlement agreements related to CINVANTI or other products.
Read more →HRTX▼ -21%on this news
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Heron Therapeutics reported its Q1 2026 financial results, highlighting a 32% year-over-year revenue growth in its Acute Care franchise, contributing to a total net revenue of $34.7 million. The company reaffirmed its full-year guidance of $173 to $183 million in net revenue despite a decrease in total revenue compared to the previous year. APONVIE and ZYNRELEF showed strong demand, with notable increases in their revenue contributions. However, a significant decline in CINVANTI revenue and total revenue compared to the previous year raised concerns about market challenges.
Read more →HRTXHeron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
Heron Therapeutics, Inc. will host a conference call on May 11, 2026, to report its first quarter financial results and discuss business highlights. The call will be accessible via phone and webcast, with an archive available for 60 days. The company continues to focus on developing therapeutic innovations for acute care and oncology patients.
Read more →HRTX▲ +11.1%on this news
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
Heron Therapeutics announced their financial results for the fourth quarter and full year of 2025, reporting a 65% growth in net revenue driven by their acute care franchise, particularly ZYNRELEF and APONVIE. They achieved $154.9 million in total net revenue for 2025 and provided optimistic guidance for 2026, anticipating net revenue between $173 million and $183 million. Despite the promising outlook, the oncology franchise faced challenges with a significant revenue decline, raising some concerns about portfolio performance in that area.
Read more →HRTXHeron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Heron Therapeutics, a biotechnology company, will host a conference call on February 26, 2026, to discuss its fourth quarter and full year 2025 financial results. The call will provide insights into the company's recent business highlights and can be accessed via phone or webcast. An archive of the call will be available for 60 days on their website.
Read more →HRTX▲ +9.4%on this news
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth
Heron Therapeutics has announced its preliminary unaudited net revenue results for Q4 and full-year 2025, highlighting a strong performance led by ZYNRELEF. The company reported approximately $40.5 million in net revenue for Q4 2025, with ZYNRELEF contributing around $12.5 million to this figure, marking a 35% increase from Q3. In total, Heron generated approximately $154.9 million in net revenue for the year. The company expresses optimism regarding its growth trajectory and ongoing business developments.
Read more →HRTXHeron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
Heron Therapeutics announced that APONVIE (aprepitant) injectable emulsion has been included in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV). This recognition underscores APONVIE's effectiveness in preventing PONV, especially in high-risk patients. The guidelines recommend a multimodal approach to manage PONV, emphasizing the importance of long-acting antiemetics for patient recovery.
Read more →HRTXHeron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
Heron Therapeutics reported positive financial results for Q3 2025, with total net revenue reaching $38.2 million, an increase of 16.5% year-over-year. Key products like ZYNRELEF and APONVIE demonstrated substantial growth, with respective revenue increases of 49% and 173%. The company reiterated its guidance for 2025, projecting a net revenue range of $153 million to $163 million. Some products, such as SUSTOL and oncology treatments, faced revenue declines, indicating mixed performance across the portfolio.
Read more →HRTXHeron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
Heron Therapeutics has appointed Thomas Cusack to its Board of Directors, effective October 27, 2025. Cusack brings over 20 years of experience in investment management and corporate finance, including his recent role as Managing Director at Starboard Value LP. This appointment follows a Cooperation Agreement with Rubric Capital Management LP. Heron's CEO expressed enthusiasm about Cusack's potential impact on the company's growth and portfolio enhancement.
Read more →HRTXHeron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
Heron Therapeutics has adopted a Section 382 rights plan to safeguard its net operating loss carryforwards, which amount to approximately $1.37 billion. This plan aims to prevent any single investor from acquiring a significant stake that could limit the company's ability to utilize these tax attributes. The plan is effective as of August 14, 2025, and is part of the company's strategy to enhance cash flow.
Read more →HRTX▼ -28.3%on this news
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
Heron Therapeutics has completed a comprehensive capital restructuring aimed at enhancing financial flexibility and reducing total debt. This refinancing will support the company's commercial and development initiatives. The CEO highlighted that this move positions Heron for growth and eliminates near-term debt maturities. The transactions are expected to close on August 12, 2025.
Read more →HRTX▼ -28.3%on this newsshared move
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
Heron Therapeutics reported its Q2 2025 financial results, showcasing a 3.3% increase in total net revenue year-over-year, driven by strong performance in acute care and the APONVIE product line. The company anticipates continued growth, with updated financial guidance suggesting increased net revenue and adjusted EBITDA for the year. However, oncology revenue faced a decline, highlighting challenges in certain product segments.
Read more →HRTX▼ -28.3%on this newsshared move
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
Heron Therapeutics has rescheduled its second quarter 2025 earnings release and conference call to August 8, 2025, at 8:30 a.m. ET. This change allows the company to provide updates on financial results and business highlights. Participants can access the call via phone or webcast, with an archive available for 60 days post-event.
Read more →HRTXHeron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
Heron Therapeutics, Inc. will host a conference call on August 11, 2025, to report its second quarter financial results and discuss recent business highlights. The call will be accessible via phone and webcast, with an archive available for 60 days. The company emphasizes its commitment to improving patient care through innovative therapies.
Read more →HRTX▲ +13.6%on this news
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
Heron Therapeutics has reached a settlement with Mylan Pharmaceuticals to resolve patent litigations concerning CINVANTI and APONVIE. Mylan will be granted a license to market generic versions of these drugs starting June 1, 2032. The settlement follows legal actions initiated by Heron in response to Mylan's attempts to gain FDA approval for generics before the patent expiration in 2035.
Read more →HRTX▲ +13.6%on this newsshared move
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics reported strong financial results for Q1 2025, achieving record adjusted EBITDA. The company highlighted significant revenue growth, particularly for its lead product ZYNRELEF, and announced positive developments such as expanded label indications and partnerships. However, there were declines in certain oncology product revenues, indicating mixed performance across its portfolio.
Read more →HRTXHeron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
Heron Therapeutics has appointed Mark Hensley as Chief Operating Officer, effective April 28, 2025. Hensley, who has over 15 years of experience in various sales and operations roles, previously served as CEO at Veloxis Pharmaceuticals. His extensive background is expected to support Heron's strategic priorities and growth initiatives.
Read more →HRTX▲ +11.4%on this news
Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025
Heron Therapeutics, Inc. has announced plans to report its first quarter 2025 financial results via a conference call on May 6, 2025. The call will take place at 8:00 a.m. ET and will be accessible via phone and webcast. Following the event, an archive will be available on the company's website. The announcement underscores Heron’s focus on advancing healthcare through innovative therapies.
Read more →About Heron Therapeutics, Inc.
Headquarters4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next HRTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime